# Role of KDM6B in Alzheimer’s disease related dementia

> **NIH NIH R01** · UT SOUTHWESTERN MEDICAL CENTER · 2024 · $749,508

## Abstract

Project summary
Alzheimer's disease (AD) is a leading cause of dementia characterized by memory and cognitive loss interfering
with daily life. Clinical studies showed that the aberrant neuronal activity switch from hyperexcitability at the early
stage of disease to hypo-excitability at the late stage is a key feature shared in AD patients. In line with this,
levels of the principal excitatory neurotransmitter glutamate and vesicular glutamate transporters (vGluT1/2), the
primary mediators of glutamate uptake into synaptic vesicles, were decreased at the late stage of AD patients,
which contributed to AD dementia. However, the underlying pathology that leads to glutamate misregulation,
aberrant neuronal activity and synaptic dysfunction in AD dementia remains largely unknown. Our recent work
identified histone H3K27 demethylase KDM6B as a specific epigenetic regulator of synaptic plasticity and
cognitive functions. Conditional knockout of KDM6B in the excitatory neurons reduced presynaptic vesicle
numbers, spine density and glutamate release/synaptic activity in mice. Moreover, KDM6B KO mice showed
behavioral learning and memory deficits. Importantly, KDM6B expression was reduced in aged brain, while
trimethyl lysine 27 on histone H3 (H3K27me3) was increased in brain from late-onset AD patients, which were
highly correlated with their cognitive deficits. Tau was required for KDM6B recruitment and regulation in synaptic
plasticity and cognitive functions. Tau knockdown interfered with synaptic gene expression. As we know,
pathological Tau often occurred in AD and perturbed its physiological functions. These findings led us to
hypothesize that epigenetic alteration caused by KDM6B-Tau dysregulation contributes to aberrant neuronal
activity switch, cognitive impairment and AD pathogenesis. The goals of this R01 project are to 1) decipher the
role of pathological Tau in KDM6B-regulated synaptic activity and 2) determine effects of KDM6B dysregulation
on AD pathogenesis in AD mouse models. To ensure the success of the proposed project, we have assembled
a strong research team with expertise in AD-related neurodegeneration, epigenetic regulation, and synaptic
activity. If successful, this project will reveal the importance of Tau-KDM6B-dependent epigenetic priming in AD
pathogenesis and define a new epigenetic mechanism underlying synaptic hyper- and hypo-excitability switch
and cognitive impairment in AD, which may provide an innovative therapeutic target and a knowledge foundation
on development of a rational strategy to improve cognitive functions in AD patients.

## Key facts

- **NIH application ID:** 10901959
- **Project number:** 5R01AG079094-02
- **Recipient organization:** UT SOUTHWESTERN MEDICAL CENTER
- **Principal Investigator:** Yingfei Wang
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $749,508
- **Award type:** 5
- **Project period:** 2023-08-15 → 2028-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10901959

## Citation

> US National Institutes of Health, RePORTER application 10901959, Role of KDM6B in Alzheimer’s disease related dementia (5R01AG079094-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10901959. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*